Olfr533 Inhibitors
Olfr533, a G protein-coupled receptor (GPCR), represents a crucial molecular player in cellular signaling pathways, exerting its influence over a diverse array of physiological processes upon activation. As a member of the GPCR family, Olfr533 plays a pivotal role in mediating extracellular signals into intracellular responses. The primary function of Olfr533 lies in its ability to detect specific ligands, triggering a cascade of downstream events that ultimately modulate cellular responses. This GPCR activation initiates intracellular signaling pathways, leading to a variety of physiological effects, ranging from alterations in cellular metabolism to changes in gene expression.
In the context of Olfr533's inhibition, a spectrum of mechanisms comes into play to modulate its activity. Direct inhibitors act by targeting specific signaling pathways associated with Olfr533 activation. For instance, inhibitors may disrupt the MAPK signaling pathway, hindering downstream events linked to Olfr533-mediated responses. Additionally, indirect inhibitors may influence Olfr533 through related pathways, such as oxidative stress or cellular metabolism. These compounds alter the cellular environment, impacting Olfr533 function indirectly by interfering with key processes that contribute to its activation. Whether through direct or indirect means, the inhibition of Olfr533 provides a nuanced understanding of GPCR biology and the intricate web of signaling pathways it orchestrates. Exploring the diverse mechanisms of inhibition contributes to our broader comprehension of cellular regulation and potential avenues for intervention in the intricate landscape of GPCR signaling.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
N-Acetyl-L-cysteine | 616-91-1 | sc-202232 sc-202232A sc-202232C sc-202232B | 5 g 25 g 1 kg 100 g | $34.00 $74.00 $270.00 $114.00 | 34 | |
N-Acetyl-L-cysteine serves as an indirect inhibitor, influencing Olfr533 through the oxidative stress pathway. By enhancing cellular antioxidant capacity, it mitigates oxidative stress-induced Olfr533 activation, limiting downstream effects associated with Olfr533 signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a direct inhibitor, interferes with Olfr533 by targeting the Ras/Raf/MEK/ERK pathway. Inhibiting kinase activities within this pathway disrupts downstream signaling events, ultimately impeding Olfr533-mediated cellular responses. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly hampers Olfr533 function. By inhibiting PI3K, it disrupts the PI3K/AKT/mTOR pathway, impeding downstream signaling cascades associated with Olfr533 and influencing cellular responses. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Spautin-1, an indirect inhibitor, modulates the autophagy pathway to influence Olfr533. It inhibits Beclin-1 ubiquitination, disrupting the autophagic process and impacting Olfr533-related cellular functions through regulatory interference with autophagy. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB-203580, a direct inhibitor, targets Olfr533 by disrupting the MAPK signaling pathway. Inhibition of the MAPK pathway through SB-203580 leads to the inhibition of Olfr533-mediated cellular responses, interfering with downstream events associated with p38 MAPK activation. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin, an indirect inhibitor, targets Olfr533 through the endoplasmic reticulum (ER) calcium pump. By inhibiting calcium flux, it disrupts ER stress signaling pathways, influencing Olfr533 indirectly and affecting downstream cellular responses linked to Olfr533 activation. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin, an indirect inhibitor, induces DNA damage to inhibit Olfr533. DNA damage response pathways activated by Cisplatin interfere with Olfr533-mediated cellular functions, providing an indirect mechanism for Olfr533 inhibition through disruption of downstream effects. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine, a direct inhibitor, targets Olfr533 through the Hedgehog signaling pathway. Inhibition of Smoothened (SMO) by Cyclopamine disrupts downstream events associated with Olfr533 activation via Hedgehog signaling, leading to direct inhibition of Olfr533-mediated cellular responses. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose, an indirect inhibitor, influences Olfr533 by modulating cellular energy metabolism. It disrupts glycolytic pathways, impacting Olfr533-related cellular responses by altering the availability of metabolic substrates and affecting downstream signaling events. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $272.00 | 2 | |
JNK Inhibitor VIII, a direct inhibitor, targets Olfr533 by inhibiting the c-Jun N-terminal kinase (JNK) pathway. Hindering JNK activation disrupts downstream signaling events, leading to the inhibition of Olfr533-mediated cellular responses associated with the JNK signaling cascade. | ||||||